The tech industry might remain under pressure amid lingering macroeconomic uncertainties. Hence, investors could avoid tech ETFs VanEck Digital Transformation (DAPP), SPDR S&P Internet (XWEB), and Direxion Daily Cloud Computing Bull 2X (CLDL). Read more to learn why. Rising interest rates, inflation concerns, and the recent collapse of yet another financial lender have led to…
Opinions expressed by Entrepreneur contributors are their own. Small business owners these days have a lot on their minds — and too much on their plates. Sky-high borrowing costs, corrosive inflation, a slowing economy and tighter credit conditions are keeping them on edge. Along with your entrepreneurial cohort, you’re probably working overtime, redoubling efforts to…
Running a one person business is challenging, but we’re here to help you. Tune into our video series, Solopreneur Office Hours, as our expert, Terry Rice, answers your most pressing questions. Running a one person business is challenging, but it doesn’t have to be confusing. In our new series, Office Hours for Solopreneurs with Terry…
Investors have been in a state of limbo all year long trying to determine if still in a bear market or has the new bull already emerged? 4,200 on the S&P 500 (SPY) being the key level. Interestingly, the Fed announcement on Wednesday 5/3 could be the key catalyst to settle this dispute once and…
Whether you’re a real estate investor, entrepreneur or simply a finance-savvy consumer, financial technology (fintech) has allowed great strides when it comes to optimizing real estate investments. Fintech involves using blockchain, big data, cloud computing or artificial intelligence to complete financial transactions. Most property technology (proptech) overlaps with fintech, allowing real estate agents and investors…
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers, inflammatory diseases and sexual dysfunction. It targets the A3 adenosine receptor (A3AR) and creates small molecule therapies to bind or stick to the A3 receptor and disrupt the growth of pathological cells. The A3AR has been targeted for…
Ecolab (NYSE: ECL) has had its share of issues over the last 2 years, but those are centered on share prices which have retreated to reasonable levels. The stock soared after COVID-19, driven by the expectation sanitation services and products would be in high demand, but that demand never materialized to the extent that share…
The Chinese have a saying concerning the reality of the haves and have-nots and how they should deal with their finances. Those who have riches or inherit them can afford to speculate with small sums of money, while those who do not have wealth and are part of the middle class have to speculate with…
Pfizer (NYSE: PFE) was expected to post a significant decline in revenue and earnings because of the slowing COVID business, and it did. However, the takeaway from the report is that business is better than expected, the company is growing at the core level, and the pipeline of new products is robust. That’s important because…
Opinions expressed by Entrepreneur contributors are their own. As a Black woman entrepreneur, I’ve managed to run a successful diversity, equity and inclusion (DEI) consultancy for the past six years. But I promise, it wasn’t easy. For me, becoming an entrepreneur looked like getting a doctorate in organizational leadership and working my way to owning…